Aguilera JT

Language: Spanish
References: 10
Page: 681-683
PDF size: 137.25 Kb.

ABSTRACT

Systemic Amyloidosis is a disease caused by abnormal deposition of misfolded proteins produced by clonal expansion of plasma cells in the bone marrow, with very heterogeneous manifestations affecting various organs mainly kidneys, heart and liver. It is essential to suspect the presence of this pathology, because the diagnosis is not easy and without treatment it leads to death within a few years.

REFERENCES

1. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:287-294.

2. Connors L et al: Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of trensthyretin V1221 amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 158:607,2009

3. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:180-186.

4. Goldmann L, Schafer A, et Al (2012) Amyloidosis. In Goldman’s Cecil medicine (24Ed pp 1243-1245) Philadelphia.

5. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083-1093.

6. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12-18.

7. Longo D, Fauci A, et Al (2012) Amiloidosis. En Harrison: Principios de medicina interna (18va Ed pp 945-950) México DF.

8. Merlini G, Bellotti V, Molecular mechanism of amyloidosis. N Engl J Med 349:583, 2003.

9. Pérez S. Amiloidosis: Enfermedad Desafiante en su Diagnóstico y Tratamiento Rev. chil. reumatol. 2009; 25(1):37-41.

10. Sanchorawala V et al: Longterm outcome of patients with AL amyloidosis treated with highdose melphalan and stem-cell transplantation. Blood 110: 3561, 2007.